Suvorexant: The first orexin receptor antagonist to treat insomnia

Journal of Pharmacology and Pharmacotherapeutics

Volumn 6, Issue 2, 2015, Pages 118-121

  Dubey, Ashok K ^a   Handu, Shailendra S ^a   Mediratta, Pramod K ^a  

^a SHARDA UNIVERSITY   (India)

Author keywords

Insomnia; orexin receptor antagonist; suvorexant

Indexed keywords

OREXIN RECEPTOR; PLACEBO; SUVOREXANT;

ABNORMAL DREAMING; AMNESIA; ARTICLE; BEDTIME DOSAGE; CATAPLEXY; CONFUSION; DAYTIME SOMNOLENCE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GAIT DISORDER; HUMAN; HYPNAGOGIC HALLUCINATION; INSOMNIA; MOTOR DYSFUNCTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SLEEP WALKING; SOMNOLENCE; SUICIDAL IDEATION;

EID: 84928610066     PISSN: 0976500X     EISSN: 09765018     Source Type: Journal    
DOI: 10.4103/0976-500X.155496     Document Type: Article

References (19)

1. Roth T. Insomnia: Definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007;3(Suppl):S7-10.
2. Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med 2006;7:123-30.
3. Minkel J, Krystal AD. Optimizing the pharmacologic treatment of insomnia: Current status and future horizons. Sleep Med Clin 2013;8:333-50.
4. FDA News Release: FDA Approves New Type of Sleep Drug. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm 409950.htm. [Last accessed on 2014 Sep 18].
5. Kaminski T, Smolinska N, Nitkiewicz A, Przala J. Expression of orexin receptors 1 (OX1R) and 2 (OX2R) in the porcine hypothalamus during the oestrous cycle. J Physiol Pharmacol 2010;61:363-71.
6. Scammell TE, Winrow CJ. Orexin receptors: Pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 2011;51:243-66.
7. Steiner MA, Winrow CJ. Opportunities and perspectives for developing orexin receptor antagonists. Front Neurosci 2014;8:158.
8. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan- 1-yl] [5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl] methanone (MK-4305) for the treatment of insomnia. J Med Chem 2010;53:5320 - 32.
9. Suvorexant Advisory Committee Meeting Briefing Document, NDA 204569. Available from: http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/Peripheraland Central Nervous System Drugs Advisory Committee/UCM352970.pdf. [Last accessed on 2014 Sep 18].
10. Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: A randomized clinical trial of suvorexant. Neurology 2012;79:2265-74.
11. Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 2013;36:259-67.
12. Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19.
13. Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461-71.
14. Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, et al. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230.
15. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Placement of suvorexant into Schedule IV. Final rule. Fed Regist 2014;79:51243-7.
16. News: Actelion, Glaxo Stop Development of Insomnia Medicine. Available from: http://www.bloomberg.com/news/2011-01-28/actelion-glaxo-stop -development-of-insomnia-medicine-on-safety-concern.html. [Last accessed on 2014 Sep 18].
17. Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, et al. Discovery of 5''- chloro-N-[(5,6-dimethoxypyridin-2-yl) methyl]-2,2':5',3''-terpyridine-3'- carboxamide (MK-1064): A selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Chem Med Chem 2014;9:311-22.
18. Etori K, Saito YC, Tsujino N, Sakurai T. Effects of a newly developed potent orexin-2 receptor-selective antagonist, compound 1 m, on sleep/wakefulness states in mice. Front Neurosci 2014;8:8.
19. Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88.